Last reviewed · How we verify
NCT05536323
Bolus Versus Continuous Remimazolam for Anesthetic Induction
NA trial testing Remimazolam bolus in Hypotension on Induction in 62 participants. Status unknown.
1 November 2023
Quick facts
| Lead sponsor | Kangbuk Samsung Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 62 |
| Start date | 1 July 2023 |
| Primary completion | 1 November 2023 |
| Estimated completion | 1 December 2023 |
Drugs / interventions tested
- Remimazolam bolus — full drug profile →
- Remimazolam continuous — full drug profile →
Conditions studied
- Hypotension on Induction — all drugs for Hypotension on Induction →
Sponsor
Kangbuk Samsung Hospital
Who can join
19 and older, any sex, with Hypotension on Induction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset. Although it is known to cause less hemodynamic instability, the incidence hypotension is the one of the most frequent adverse events with its use. For anesthetic induction, remimazolam can be used either as bolus dose or as continuous infusion. This study is aimed to investigate the incidence of hypotension after anesthetic induction with bolus (0.14-0.33 mg/kg) or continuous (12 mg/kg/hr) remimazolam administration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05536323
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypotension on Induction
Currently open trials in the same condition.
- NCT07370103 — Carotid Artery Corrected Flow Time and Respiratory Variation of Blood Flow Peak Velocity for Prediction of Hypotension A · recruiting
- NCT06841822 — The Impact of Ultrasound-Guided Superficial and Deep Paravertebral Nerve Blocks at the Superior Costotransverse Ligament · NA · recruiting
- NCT06787404 — Evaluation of Post-Induction Hypotension Treatment with PRAM Method · active not recruiting
Other Kangbuk Samsung Hospital trials
Trials by the same sponsor.
- NCT07396961 — Consistency of ASIS Line vs. Tuffier's Line for Lumbar Level Identification · not yet recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT06773585 — Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders · not yet recruiting
- NCT06130137 — Gut Microbiome in People Living With HIV and HBV · not yet recruiting
- NCT05538741 — Hypotension After Anesthetic Induction with Remimazolam in Elderly · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05536323 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kangbuk Samsung Hospital
- Last refreshed: 2 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05536323.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing